Given the important role of adjuvants in prophylactic vaccines, identification and development of new adjuvants with enhanced efficacy and safety is necessary. The use of adjuvants with immunopotentiating properties that can direct the immune responses to humoral or cell-mediated immunity and can induce T-cell responses has made it possible to design more protective vaccines. Although current regulations focus on traditional adjuvants, notably aluminum and calcium salts, advances have been made in regulatory considerations. The regulatory agencies for the evaluation of medicinal products are actively drafting guidance on requirements for the evaluation of new adjuvants. This article briefly summarizes the most widely studied adjuvants in vaccination, including those licensed for human vaccines and the regulatory aspects relevant to adjuvant quality at development stages.

Montomoli, E., Piccirella, S., Khadang, B., Mennitto, E., Camerini, R., De Rosa, A. (2011). Current adjuvants and new perspectives in vaccine formulation. EXPERT REVIEW OF VACCINES, 10(7), 1053-1061 [10.1586/erv.11.48].

Current adjuvants and new perspectives in vaccine formulation

Montomoli, E.;Mennitto, E.;
2011-01-01

Abstract

Given the important role of adjuvants in prophylactic vaccines, identification and development of new adjuvants with enhanced efficacy and safety is necessary. The use of adjuvants with immunopotentiating properties that can direct the immune responses to humoral or cell-mediated immunity and can induce T-cell responses has made it possible to design more protective vaccines. Although current regulations focus on traditional adjuvants, notably aluminum and calcium salts, advances have been made in regulatory considerations. The regulatory agencies for the evaluation of medicinal products are actively drafting guidance on requirements for the evaluation of new adjuvants. This article briefly summarizes the most widely studied adjuvants in vaccination, including those licensed for human vaccines and the regulatory aspects relevant to adjuvant quality at development stages.
2011
Montomoli, E., Piccirella, S., Khadang, B., Mennitto, E., Camerini, R., De Rosa, A. (2011). Current adjuvants and new perspectives in vaccine formulation. EXPERT REVIEW OF VACCINES, 10(7), 1053-1061 [10.1586/erv.11.48].
File in questo prodotto:
File Dimensione Formato  
030-2011_ExpRevVacc-Montomoli.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 403.65 kB
Formato Adobe PDF
403.65 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/42997
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo